MYO16

Across TCGA pan-cancer cohorts, MYO16 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MYO16 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MYO16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO16 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

MESO, STAD, and UCEC are the cancer types where MYO16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
STAD	DFS	Median	III,IV	0.903	0.320	.006	23	view →
UCEC	DFS	Median	All	0.761	0.630	.011	22	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	6	view →
PRAD	DFS	Median	All	0.161	0.777	<.001	4	view →
SKCM	OS	Median	III,IV	0.768	0.341	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MYO16–MESO (OS)

Open the MESO breakdown →